Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

E-ISSN： 1996-3181|8|6|512-519

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.8, Iss.6, 2009-12, pp. : 512-519

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects

By Menge Til

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2445-2468

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

By Russo P.

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles

By Steven L. Galetta Clyde Markowitz

CNS Drugs, Vol. 19, Iss. 3, 2005-01 ,pp. : 239-252

Adis International

Access to resources Recommend Favorite